Library / Repair and recovery

BPC-157

Also known as Body protection compound 157, PL 14736, Bepecin

Animal studies only

Synthetic 15 amino acid peptide derived from a protein in stomach juice. Research is almost entirely in animals; only a few very small uncontrolled human pilot reports exist and no completed controlled trials.

Not an approved medicine. BPC-157 is not an approved medicine for this use in Australia or the United States. This page summarises published research for information only. It is not a recommendation to use BPC-157, and VialOwl does not sell or supply it.

Background

A synthetic 15 amino acid peptide based on a sequence from a protein found in human stomach juice, studied since the early 1990s mainly by a research group at the University of Zagreb, Croatia. It has never been approved as a medicine.

How it is thought to work

In animal and cell studies it appears to promote new blood vessel growth and tissue repair through VEGFR2, nitric oxide (Akt and eNOS) and ERK1/2 signalling, and to reduce inflammation. These mechanisms have not been confirmed in people.

What is claimed, and the evidence

Claim	Evidence	Notes
Tendon, ligament and muscle healing	Animal studies only	Many rat studies show faster healing; no completed controlled human trials.
Knee pain	Small human studies	One small uncontrolled pilot report of injection into the knee.
Interstitial cystitis (bladder pain)	Small human studies	One small uncontrolled pilot report.
Gut healing (ulcers, inflammatory bowel disease, leaky gut)	Animal studies only	Protective effects in rodent gut injury models; no human trials.
Faster injury recovery and athletic performance	No published evidence	Widely promoted online and by some clinics; not supported by human trials.

Side effects

Effect	How often	Notes
Side effects in humans	Frequency unknown	Only three tiny pilot studies exist (one had 2 participants); none reported adverse effects, which is too little data to judge safety.
Serious allergic or inflammatory reactions to unapproved peptide products Serious	Case reports	The TGA has received reports of severe allergic reactions and systemic inflammation with unapproved peptide products, and names BPC-157 as an example product.

Warnings

Human safety data are almost nonexistent; the FDA says it lacks enough information to know whether it harms people.
Because it promotes new blood vessel growth in animals, reviewers raise an unproven theoretical concern about effects on existing tumours.
In Australia it is Schedule 4 and listed in Appendix D, so possession without authority is illegal.
The TGA warned in April 2026 about unapproved peptide products, citing reports of severe allergic reactions needing adrenaline and hospitalisation, a systemic inflammatory response, and poor product quality.
Unapproved products bought online are not checked by any regulator for purity, sterility or strength; they may be contaminated, underdosed, overdosed or contain a different substance to the label.

Regulatory status

Australia: Not included on the ARTG (unapproved). Schedule 4 (Prescription Only Medicine) in the Poisons Standard, also listed in Appendix D clause 5 (possession without authority is illegal). TGA names it as an example of an unapproved peptide product.
United States: Not FDA approved. Nomination withdrawn and removed from 503A Category 2 in April 2026. In July 2026 an FDA advisory committee voted 8 to 6 to recommend it for the 503A bulks list; FDA has not finalised this.

Sources

Also in Repair and recovery

From the VialOwl library, reviewed 26 September 2026. For education and general information. It is not medical advice and not a recommendation to use BPC-157.